Benzinga | Jan 19, 2021 07:01AM EST

C4 Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CFT7455, An Orally Bioavailable MonoDAC For Hematologic Malignancies

WATERTOWN, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for its lead product candidate, CFT7455, an orally bioavailable MonoDAC (Monofunctional Degradation Activating Compound) targeting IKZF1/3 for the treatment of hematologic malignancies such as multiple myeloma and non-Hodgkin lymphomas, including peripheral T cell lymphoma and mantle cell lymphoma. The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed Phase 1/2 clinical trial for CFT7455.